Leqembi Label Recommends Alzheimer’s Patient Registry: A Nod To Medicare Evidence Demands?
Executive Summary
FDA-approved language recommending ongoing patient monitoring through a registry is unusual but not unprecedented to address potential safety concerns.
You may also be interested in...
Leqembi Safety Is Focus Of Three Postmarketing Requirements From US FDA
Required studies will assess the risks of ARIA and intracerebral hemorrhage, as well as safety in ApoE ε4 homozygotes. For the required registry-based study, the FDA suggests use of the ALZ-NET platform with no mention of CMS’ newly established registry, which may lack the level of detailed information needed to satisfy the drug regulator’s request.
Medicare And Alzheimer’s Drugs: Pressure To Relax Coverage Restrictions Rising Wtih Donanemab Data
Lilly's donanemab may be the second amyloid-targeting drug for Alzheimer’s headed toward a traditional US Food and Drug Administration approval this year, setting up a showdown with Medicare over its coverage with evidence development requirements.
Leqembi Coverage By Veterans Affairs Department Sign Of Success For Eisai’s Payer Engagement Strategy
Alzheimer’s product is following a different playbook than Aduhlem, reflecting better data – and hard-earned lessons. Eisai estimates that 80-90% of veterans who are eligible for Leqembi treatment based on the FDA label would also fit the VA’s criteria.